TD Cowen Cuts Abbott Laboratories (ABT) Price Target to $118

TD Cowen maintained its Buy rating on Abbott Laboratories on October 22, 2026, while lowering its price target from $135.00 to $118.00. According to the research note released on October 22, 2026, the firm kept its positive stance on the healthcare company even as it adjusted its expectations downward. Abbott Laboratories operates globally, developing and selling health care products across four segments including medical devices, diagnostics, nutritional products, and established pharmaceuticals.

ABT Abbott Laboratories

$100.51 ▼ -17.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

TD Cowen's Call on Abbott Laboratories

On October 22, 2026, TD Cowen issued its updated research note on Abbott Laboratories, reiterating a Buy rating while reducing the price target to $118.00 from $135.00. The forward-looking rating points to the firm's continued confidence in the medical device maker's business lines despite the lower target.

Other Institutional Activity in Abbott Laboratories

Capital International Investors trimmed its holdings by 2,842,222 shares, ending the quarter ended June 30, 2026, with 34,654,113 shares worth about $3,538,704,674.

Abbott Laboratories Stock Down 1.1%

Abbott Laboratories recently traded around $101.34 as of October 22, 2026, sitting about 0.8% below its event-day close of $102.11. The shares are down about 23.2% from their 52-week high of $132.03 and sit up about 23.6% from their 52-week low of $81.97. The stock trades below its 50-day moving average of $105.49.

Recent Earnings

Abbott Laboratories reported trailing-twelve-month revenue of $46,584,999,936 alongside trailing-twelve-month earnings per share of $2.69. The company posted a net profit margin of 11.6% and a return on equity of 10.6%, with year-over-year revenue growth reaching 13.0%.

Dividend

Abbott Laboratories pays an annual dividend rate of $2.52 per share, yielding 2.46%. The company's dividend payout ratio stands at 78.7%.

Insider Buying and Selling at Abbott Laboratories

Insider transactions included a purchase by Director John G. Stratton, who bought 2,000 shares on May 7, 2026, at an average price of $86.82 for a total value of $173,640. On the selling side, Officer Louis H Morrone sold 5,850 shares on August 11, 2026, at $109.83 for $642,506. Chief Executive Officer Robert B. Ford sold 398,832 shares on August 25, 2026, valued at $46,204,798. Finally, Officer John A. Mccoy Jr sold 27 shares on September 2, 2026, at $109.54 for $2,958.

Analysts Set New Price Targets

Alongside TD Cowen, several other firms updated their views on October 22, 2026. RBC Capital maintained an Outperform rating while lowering its target from $130.00 to $125.00. Wells Fargo maintained an Overweight rating and raised its target from $112.00 to $119.00. JP Morgan maintained an Overweight rating while cutting its target from $120.00 to $118.00. Baird maintained an Outperform rating and lifted its target from $121.00 to $123.00. Overall, the stock carries a strong_buy consensus recommendation from 26 analyst opinions, with a mean price target of $120.41.

About Abbott Laboratories

Abbott Laboratories researches, develops, and delivers a wide array of health care products to patients and providers around the globe. Its operations span medical technology, diagnostics, nutritional formulas, and branded generic medicines. The firm's diverse product portfolio helps anchor its position in the broader healthcare sector as it navigates market changes.

Bottom Line

TD Cowen's decision to keep a Buy rating while lowering its price target highlights shifting expectations on Wall Street for Abbott Laboratories. Investors will likely watch the company's next financial results and institutional filing updates to gauge whether demand across its medical device and diagnostic segments supports these updated price targets.